PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 190 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 5.26 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $238,773 | -26.3% | 6,891 | -38.4% | 0.03% | -17.1% |
Q1 2024 | $323,785 | +111.5% | 11,192 | +67.7% | 0.04% | +36.7% |
Q4 2023 | $153,058 | +522.9% | 6,675 | +353.2% | 0.03% | +328.6% |
Q3 2023 | $24,570 | +18.6% | 1,473 | +96.4% | 0.01% | +16.7% |
Q2 2023 | $20,715 | +35.0% | 750 | +12.4% | 0.01% | +20.0% |
Q1 2023 | $15,341 | +181.2% | 667 | +33.4% | 0.01% | +150.0% |
Q4 2022 | $5,455 | +36.4% | 500 | +8.7% | 0.00% | 0.0% |
Q3 2022 | $4,000 | – | 460 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Johnson & Johnson Innovation - JJDC, Inc. | 2,449,183 | $43,253,000 | 8.50% |
BVF INC/IL | 2,367,288 | $41,806,000 | 2.58% |
RTW INVESTMENTS, LP | 3,383,208 | $59,747,000 | 1.68% |
Novo Holdings A/S | 824,169 | $14,555,000 | 0.94% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,013,495 | $17,898,000 | 0.52% |
Sofinnova Investments, Inc. | 326,064 | $5,758,000 | 0.36% |
FARALLON CAPITAL MANAGEMENT LLC | 2,500,000 | $44,150,000 | 0.35% |
Virtus ETF Advisers LLC | 21,639 | $382,000 | 0.18% |
Baker Brothers Advisors | 1,911,446 | $33,756,000 | 0.15% |
King Wealth Management Group | 22,000 | $389,000 | 0.11% |